Reata Pharmaceuticals, Inc.
RETA · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $4,232,044 | $3,359,318 | $1,379,848 | $918,173 |
| - Cash | $48,843 | $84,940 | $42,312 | $31,918 |
| + Debt | $166,003 | $117,933 | $119,464 | $140,713 |
| Enterprise Value | $4,349,204 | $3,392,311 | $1,457,000 | $1,026,968 |
| Revenue | $22,746 | $195 | $914 | $540 |
| % Growth | 11,564.6% | -78.7% | 69.3% | – |
| Gross Profit | $21,900 | $195 | $914 | $540 |
| % Margin | 96.3% | 100% | 100% | 100% |
| EBITDA | $193,291 | -$110,167 | -$117,222 | -$68,066 |
| % Margin | 849.8% | -56,495.9% | -12,825.2% | -12,604.8% |
| Net Income | $192,998 | -$110,762 | -$85,502 | -$76,791 |
| % Margin | 848.5% | -56,801% | -9,354.7% | -14,220.6% |
| EPS Diluted | 4.65 | -3 | -2.35 | -2.1 |
| % Growth | 255% | -27.7% | -11.9% | – |
| Operating Cash Flow | -$69,928 | -$81,449 | -$50,426 | -$46,534 |
| Capital Expenditures | -$274 | -$141 | -$367 | -$341 |
| Free Cash Flow | -$70,202 | -$81,590 | -$50,793 | -$46,875 |